// App-Quantinova.ai

3594 : Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm

Researchers

Presenter

  • Bruno C. Medeiros

Principal Investigators

  • Anthony Selwyn Stein

  • John M. Pagel

  • Roland B. Walter

  • Cynthia Parks

  • Elihu H. Estey

  • Frederick R. Appelbaum

  • Bart L Scott

  • Colleen Delaney

  • Megan Othus

  • Paul C. Hendrie

  • Kelda M. Gardner

  • Stephen Petersdorf

Medical Centers

  • University of Washington, Seattle, WA

  • Department of Medicine/Division of Hematology, University of Washington, Seattle, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

  • Myeloid neoplasms

  • Alpha-thalassemia myelodysplasia syndrome

  • Acute myelocytic leukemia

  • Myelofibrosis

  • Hyperglycemia

  • Septic shock

  • Solid malignancies

Biomarkers

  • Granulocyte colony-stimulating factor

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • Clofarabine

  • fludarabine tablet

  • Cytarabine liposomal

  • Filgrastim

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT01101880

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved